S&P 500 7,568.92 +0.36%
Nasdaq 25,372.01 +0.83%
S&P/TSX 35,532.28 −0.75%
Apple 331.90 −1.90%
Nvidia 206.69 +2.29%
Microsoft 520.99 +2.74%
Shopify 200.19 −8.02%
Royal Bank 285.42 −0.28%
CAD/USD 0.7171 +0.27%
PRE-MKT · 05:15 ET
Market ClerkRecap
Wed Nov 4 · pre-market3 signals on Nov 3175 insider buys this week · $365.2MCIRO short report next: Nov 15The week ahead
CE
INSIDER · DNTH · Dianthus Therapeutics, Inc. /DE/ · CHIEF ACCOUNTING OFFICER

CARR EDWARD

Every open-market transaction filed under this name, Sep 17 to Sep 17.

Filings
5
0 buys · 5 sells
Bought
—
open market, at cost
Sold
$2M
includes scheduled sales
Buys since
—
no current price on file

Filings

SEC FORM 4 · OPEN MARKET
TradedTickerCompanyRoleTypeSharesPriceValueSince
Sep 17DNTHDianthus Therapeutics, Inc. /DE/CHIEF ACCOUNTING OFFICERSell700$104.39$73K—
Sep 17DNTHDianthus Therapeutics, Inc. /DE/CHIEF ACCOUNTING OFFICERSell1,100$103.20$114K—
Sep 17DNTHDianthus Therapeutics, Inc. /DE/CHIEF ACCOUNTING OFFICERSell3,501$102.39$358K—
Sep 17DNTHDianthus Therapeutics, Inc. /DE/CHIEF ACCOUNTING OFFICERSell6,771$101.37$686K—
Sep 17DNTHDianthus Therapeutics, Inc. /DE/CHIEF ACCOUNTING OFFICERSell7,928$100.43$796K—

"Since" is the stock's move from the filed price to the latest quote on file, not a scored call. Open-market purchases and sales only; option exercises and grants are excluded.